Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016', provides an overview of the Hypertrophic Cardiomyopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy - The report reviews pipeline therapeutics for Hypertrophic Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hypertrophic Cardiomyopathy therapeutics and enlists all their major and minor projects - The report assesses Hypertrophic Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hypertrophic Cardiomyopathy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hypertrophic Cardiomyopathy Overview 6 Therapeutics Development 7 Pipeline Products for Hypertrophic Cardiomyopathy - Overview 7 Pipeline Products for Hypertrophic Cardiomyopathy - Comparative Analysis 8 Hypertrophic Cardiomyopathy - Therapeutics under Development by Companies 9 Hypertrophic Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 10 Hypertrophic Cardiomyopathy - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Hypertrophic Cardiomyopathy - Products under Development by Companies 13 Hypertrophic Cardiomyopathy - Products under Investigation by Universities/Institutes 14 Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development 15 Gilead Sciences, Inc. 15 Heart Metabolics Limited 16 miRagen Therapeutics, Inc. 17 MyoKardia, Inc. 18 Hypertrophic Cardiomyopathy - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 27 eleclazine - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 HCM-2 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 MGN-9103 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 MYK-461 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 perhexiline maleate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ranolazine ER - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule for Cardiac Hypertrophy - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Hypertrophic Cardiomyopathy - Recent Pipeline Updates 38 Hypertrophic Cardiomyopathy - Dormant Projects 42 Hypertrophic Cardiomyopathy - Discontinued Products 43 Hypertrophic Cardiomyopathy - Product Development Milestones 44 Featured News & Press Releases 44 May 02, 2016: MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy 44 Mar 15, 2016: Heart Metabolics Announces Multiple Senior Appointments to Management Team 44 Feb 04, 2016: MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy 45 Oct 06, 2015: MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy 46 Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy 46 Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy 47 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for Hypertrophic Cardiomyopathy, H1 2016 7 Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Hypertrophic Cardiomyopathy - Pipeline by Gilead Sciences, Inc., H1 2016 15 Hypertrophic Cardiomyopathy - Pipeline by Heart Metabolics Limited, H1 2016 16 Hypertrophic Cardiomyopathy - Pipeline by miRagen Therapeutics, Inc., H1 2016 17 Hypertrophic Cardiomyopathy - Pipeline by MyoKardia, Inc., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Hypertrophic Cardiomyopathy Therapeutics - Recent Pipeline Updates, H1 2016 38 Hypertrophic Cardiomyopathy - Dormant Projects, H1 2016 42 Hypertrophic Cardiomyopathy - Discontinued Products, H1 2016 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
